Literature DB >> 18044697

A comparison of the mini mental state exam to the Montreal cognitive assessment in identifying cognitive deficits in Parkinson's disease.

Cindy Zadikoff1, Susan H Fox, David F Tang-Wai, Teri Thomsen, Rob M A de Bie, Pettarusup Wadia, Janis Miyasaki, Sarah Duff-Canning, Anthony E Lang, Connie Marras.   

Abstract

Dementia is an important and increasingly recognized problem in Parkinson's disease (PD). The mini-mental state examination (MMSE) often fails to detect early cognitive decline. The Montreal cognitive assessment (MoCA) is a brief tool developed to detect mild cognitive impairment that assesses a broader range of domains frequently affected in PD. The scores on the MMSE and the MoCA were compared in 88 patients with PD. A pronounced ceiling effect was observed with the MMSE but not with the MoCA. The range and standard deviation of scores was larger with the MoCA(7-30, 4.26) than with the MMSE(16-30, 2.55). The percentage of subjects scoring below a cutoff of 26/30 (used by others to detect mild cognitive impairment) was higher on the MoCA (32%) than on the MMSE (11%) (P < 0.000002). Compared to the MMSE, the MoCA may be a more sensitive tool to identify early cognitive impairment in PD. 2007 Movement Disorder Society

Entities:  

Mesh:

Year:  2008        PMID: 18044697     DOI: 10.1002/mds.21837

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  89 in total

1.  Screening for DSM-IV-TR cognitive disorder NOS in Parkinson's disease using the Mattis Dementia Rating Scale.

Authors:  Gregory M Pontone; Justin Palanci; James R Williams; Susan Spear Bassett
Journal:  Int J Geriatr Psychiatry       Date:  2012-05-24       Impact factor: 3.485

2.  Utility of the NeuroTrax computerized battery for cognitive screening in Parkinson's disease: comparison with the MMSE and the MoCA.

Authors:  B Hanna-Pladdy; A Enslein; M Fray; B J Gajewski; R Pahwa; K E Lyons
Journal:  Int J Neurosci       Date:  2010-08       Impact factor: 2.292

3.  A recommended scale for cognitive screening in clinical trials of Parkinson's disease.

Authors:  Kelvin L Chou; Melissa M Amick; Jason Brandt; Richard Camicioli; Karen Frei; Darren Gitelman; Jennifer Goldman; John Growdon; Howard I Hurtig; Bonnie Levin; Irene Litvan; Laura Marsh; Tanya Simuni; Alexander I Tröster; Ergun Y Uc
Journal:  Mov Disord       Date:  2010-11-15       Impact factor: 10.338

4.  Mild cognitive impairment is common in Parkinson's disease patients with normal Mini-Mental State Examination (MMSE) scores.

Authors:  Eugenia Mamikonyan; Paul J Moberg; Andrew Siderowf; John E Duda; Tom Ten Have; Howard I Hurtig; Matthew B Stern; Daniel Weintraub
Journal:  Parkinsonism Relat Disord       Date:  2008-07-02       Impact factor: 4.891

Review 5.  MDS Task Force on mild cognitive impairment in Parkinson's disease: critical review of PD-MCI.

Authors:  Irene Litvan; Dag Aarsland; Charles H Adler; Jennifer G Goldman; Jaime Kulisevsky; Brit Mollenhauer; Maria C Rodriguez-Oroz; Alexander I Tröster; Daniel Weintraub
Journal:  Mov Disord       Date:  2011-06-09       Impact factor: 10.338

6.  Use of the Montreal Cognitive Assessment and Alzheimer's Disease-8 as cognitive screening measures in Parkinson's disease.

Authors:  Daniel S Brown; Ira H Bernstein; Shawn M McClintock; C Munro Cullum; Richard B Dewey; Mustafa Husain; Laura H Lacritz
Journal:  Int J Geriatr Psychiatry       Date:  2015-07-14       Impact factor: 3.485

7.  Montreal cognitive assessment performance in patients with Parkinson's disease with "normal" global cognition according to mini-mental state examination score.

Authors:  Sarra Nazem; Andrew D Siderowf; John E Duda; Tom Ten Have; Amy Colcher; Stacy S Horn; Paul J Moberg; Jayne R Wilkinson; Howard I Hurtig; Matthew B Stern; Daniel Weintraub
Journal:  J Am Geriatr Soc       Date:  2008-12-10       Impact factor: 5.562

8.  Cognitive function and other non-motor features in non-demented Parkinson's disease motor subtypes.

Authors:  Talia Herman; Aner Weiss; Marina Brozgol; Adi Wilf-Yarkoni; Nir Giladi; Jeffrey M Hausdorff
Journal:  J Neural Transm (Vienna)       Date:  2014-12-10       Impact factor: 3.575

9.  Evaluation and management of the non-motor features of Parkinson's disease.

Authors:  Steven Wishart; Graeme J A Macphee
Journal:  Ther Adv Chronic Dis       Date:  2011-03       Impact factor: 5.091

10.  Cognitive performance on the mini-mental state examination and the montreal cognitive assessment across the healthy adult lifespan.

Authors:  Shea Gluhm; Jody Goldstein; Kiet Loc; Alexandra Colt; Charles Van Liew; Jody Corey-Bloom
Journal:  Cogn Behav Neurol       Date:  2013-03       Impact factor: 1.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.